- Home
- AKA vs NLSP Comparison
AKA vs NLSP Comparison
Compare AKA & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- NLSP
- Stock Information
- Founded
- AKA 2018
- NLSP 2015
- Country
- AKA United States
- NLSP Switzerland
- Employees
- AKA N/A
- NLSP N/A
- Industry
- AKA Catalog/Specialty Distribution
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- NLSP Health Care
- Exchange
- AKA Nasdaq
- NLSP Nasdaq
- Market Cap
- AKA 110.4M
- NLSP 12.4M
- IPO Year
- AKA 2021
- NLSP 2021
- Fundamental
- Price
- AKA $11.28
- NLSP $2.13
- Analyst Decision
- AKA Buy
- NLSP
- Analyst Count
- AKA 4
- NLSP 0
- Target Price
- AKA $22.50
- NLSP N/A
- AVG Volume (30 Days)
- AKA 7.6K
- NLSP 268.4K
- Earning Date
- AKA 08-06-2025
- NLSP 07-22-2025
- Dividend Yield
- AKA N/A
- NLSP N/A
- EPS Growth
- AKA N/A
- NLSP N/A
- EPS
- AKA N/A
- NLSP N/A
- Revenue
- AKA $586,514,000.00
- NLSP N/A
- Revenue This Year
- AKA $6.60
- NLSP N/A
- Revenue Next Year
- AKA $4.14
- NLSP N/A
- P/E Ratio
- AKA N/A
- NLSP N/A
- Revenue Growth
- AKA 8.09
- NLSP N/A
- 52 Week Low
- AKA $7.00
- NLSP $1.30
- 52 Week High
- AKA $32.25
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- AKA 48.54
- NLSP 43.58
- Support Level
- AKA $10.75
- NLSP $2.20
- Resistance Level
- AKA $11.59
- NLSP $2.33
- Average True Range (ATR)
- AKA 0.62
- NLSP 0.25
- MACD
- AKA 0.00
- NLSP -0.07
- Stochastic Oscillator
- AKA 47.91
- NLSP 6.86
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.